Merck (MRK) Total Non-Current Liabilities (2009 - 2026)
Merck (MRK) posted quarterly Total Non-Current Liabilities of $121.0 billion for Q1 2026, up 11.59% year-over-year from $108.5 billion in Q1 2025, and down 6.3% quarter-over-quarter from $129.2 billion in Q4 2025.
Merck (MRK) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Total Non-Current Liabilities for 17 consecutive years, with $121.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 11.59% year-over-year to $121.0 billion; the TTM figure through Mar 2026 stood at $121.0 billion (up 11.59% YoY), while the FY2025 annual figure was $129.2 billion, changed N/A from the prior year.
- Total Non-Current Liabilities eased to $121.0 billion in Q1 2026 per MRK's latest filing, from $129.2 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $129.2 billion in Q4 2025 and bottomed at $600.0 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $42.6 billion across 5 years, with a median of $600.0 million in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities changed 0.0% — and 2025, when it surged 14362.27%.
- Merck's Total Non-Current Liabilities stood at $600.0 million in 2022, then changed by 0.0% to $600.0 million in 2023, then climbed by 25.0% to $750.0 million in 2024, then jumped by 17123.73% to $129.2 billion in 2025, then slipped by 6.3% to $121.0 billion in 2026.
- Business Quant data shows MRK's Total Non-Current Liabilities at $121.0 billion in Q1 2026, $129.2 billion in Q4 2025, and $121.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 32.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.23 Bn |
| Mar 31, 2026 | 121.04 Bn |
| Dec 31, 2025 | 129.18 Bn |
| Sep 30, 2025 | 121.89 Bn |
| Jun 30, 2025 | 110.49 Bn |
| Mar 31, 2025 | 108.47 Bn |
| Mar 31, 2024 | 750.00 Mn |
| Dec 31, 2023 | 600.00 Mn |
| Sep 30, 2023 | 600.00 Mn |
| Jun 30, 2023 | 600.00 Mn |
| Mar 31, 2023 | 600.00 Mn |
| Dec 31, 2022 | 600.00 Mn |
| Sep 30, 2022 | 600.00 Mn |
| Jun 30, 2022 | 600.00 Mn |
| Mar 31, 2022 | 600.00 Mn |
| Jun 30, 2021 | 400.00 Mn |
| Mar 31, 2021 | 400.00 Mn |
| Dec 31, 2020 | 600.00 Mn |
| Sep 30, 2020 | 570.00 Mn |
| Jun 30, 2020 | 570.00 Mn |